排序方式: 共有24条查询结果,搜索用时 15 毫秒
1.
2.
Objective To evaluate the clinical diagnostic application and operative efficacy of the expression of NKG2D in peripheral blood CD+8 NKT cell and its ligand sMICA in patients with esophageal or cardiac carcinoma.Methods The peripheral blood NKG2D positive CD+8 NKT cell percentage was concomitantly determined by flow cytometry in 53 preoperative patients including 29 postoperative patients with esophageal or cardiac carcinoma and 30 healthy controls.The serum sMICA was determined by ELISA.Results The peripheral blood NKG2D positive CD+8 NKT cell percentage in patients was significantly lower than that in controls [(77.632±8.972) % vs (89.053±6.515) %] (t = -6.113,P <0.05); with stage Ⅱ,Ⅲ,Ⅳ,it decreased significantly in order (F = 99.251,P <0.01);with lymph node metastasis lower than that without lymph node metastasis (t = -10.384,P <0.01); squamous carcinoma was higher than adenocarcinoma (t =9.899,P <0.01); postoperative was significantly higher than preoperative (t =-4.319,P <0.01).The level of serum sMICA in patients was significantly higher than that in controls [(326.28±85.407) pg/ml vs (210.00±92.560) pg/ml](t =7.292,P <0.01); with stage Ⅱ,Ⅲ,Ⅳ,it increased significautly in order (F =63.355,P <0.01); with lymph node metastasis higher than that without lymph node metastasis (t =7.770,P <0.01); squamous carcinoma was lower than adenocarcinoma (t =-7.593,P<0.01); postoperative was significantly lower than preoperative (t =7.027,P <0.01).Serum sMICA could inhibit peripheral blood CD+8 NKT cell activation receptor NKG2D (F =142.773,P <0.05),determination coefficient R2 = 0.7368.Conclusion The level of peripheral blood CD+8NKT cell activation receptor NKG2D and serum sMICA in patients could be an assistant indicator for 相似文献
3.
<正> 乳癌是我国女性常见的恶性肿瘤。进一步了解乳癌患者的免疫状态,如何应用免疫治疗,以提高术后生存率,延长生存期,乃是乳癌研究的一个新课题。现将我们在这方面进行的初步工作小结如下: 相似文献
4.
目的 探讨贲门癌患者的免疫功能异常及其临床意义。方法 采用流式细胞术(FCM)和酶联免疫吸附(ELISA)方法分别检测 56例贲门癌患者、15名健康人外周血中CD+4 CDhi25 CDlow127 调节性T细胞(Treg细胞)和血清IL-10、TGF-β1水平,结合临床资料进行分析。结果 56例贲门癌患者外周血中CD+4 CDhi25 CDlow127 Treg细胞占CD+4淋巴细胞的比例为(5.73±1.56)%,与健康对照组的(4.45±1.06)%相比,差异有统计学意义(P<0.01);血清中IL-10和TGF-β1含量均明显高于健康对照(P<0.05)。贲门癌患者外周血CD+4 CDhi25 CDlow127 Treg细胞水平与血清IL-10和TGF-β1含量呈正相关。贲门癌患者外周血CD+4 CDhi25 CDlow127 Treg 细胞数量与患者临床分期、淋巴结转移有关。结论 贲门癌患者外周血中CD+4 CDhi25 CDlow127 Treg细胞表达增高,与临床分期有关,提示Treg水平异常与贲门癌的发生发展密切相关。 相似文献
5.
Objective To analyse the dysfunction of immunity and clinical significance in patients with cardiac cancer.Methods The level of CD4+ CD25hi CD127low Treg cells were detected by flow cytometry (FCM),and serum IL-10 and TGF-β1 levels were determined by enzyme linked immunosorbent assay (ELISA) kit in 56 patients with cardiac cancer.15 healthy volunteers were tested as normal controls.The clinical data of each patient were collected and analyzed. Results There was a significantly higher percentage of CD4+ CD25hi CD127low Treg cells in patients with cardiac cancer (5.73±1.56)% than that (4.45±1.06)% of healthy volunteers (P<0.01).The IL-10 and TGF-β1 levels in the serum of patients with cardiac cancer were also significantly higher than that of healthy volunteers (P<0.05).There was a positive correlation between levels of IL-10.TGF-β1 and the levels of CD4+ CD25hi CD127low Treg cells.The number of CD4+ CD25hi CD127low regulatory T cells in the peripheral blood of cardiac cancer patients were significantly correlated with clinical stages and metastasis lymph node.Conclusion The CD4+ CD25hi CD127low Treg cells in the peripheral blood of cardiac cancer patients is significantly increased in comparison with that in healthy volunteers,and was also correlated with different stages.The abnormal levels of CD4+ CD25hi CD127low Treg cells may be related to tumor progression in patients with cardiac cancer. 相似文献
6.
恶性血液系统肿瘤自体干细胞移植前后免疫功能的变化 总被引:1,自引:0,他引:1
高剂量的放化疗加上自体造血干细胞移植 (AHSCT)已大大地提高了各种恶性血液系肿瘤的疗效 ,并已成为其根治性治疗的重要措施之一。然而 ,大剂量化疗不只杀伤肿瘤细胞 ,而且对患者的免疫功能也有严重的损伤。但有关大剂量化疗后免疫功能的报道不多 ,现将我们近几年来有关这方面的工作报道如下。1 对象与方法1. 1 对象 10例恶性淋巴瘤 (其中NHL7例 ,HD3例 ) ,1例恶性多发性骨髓瘤。男性 6例 ,女性 5例。年龄 10岁~5 8岁 ,中位年龄为 30岁。淋巴瘤分期 : A2例 , A4例 , B4例。正常对照 30例。1.2 测定方法 1)淋巴细胞转化试验 :3… 相似文献
7.
应用析因设计,对20例癌患者的血清及淋巴细胞在淋转抑制中的作用,进行了分析。结果表明:(1) 癌患者的血清具有一定的免疫抑制作用;(2) 癌患者的淋巴细胞对PHA的反应能力,也明显低于正常对照;(3) 在癌患者的免疫能力受损的机制中,淋巴细胞的作用较之血清更为重要。 相似文献
8.
9.
目的 探讨艾迪注射液辅助化疗对中晚期非小细胞肺癌(NSCLC)患者外周血CD+4CDhi25CDlow127调节性T(Treg)细胞表达的影响.方法 60例NSCLC患者随机分为化疗加艾迪注射液组(观察组)和单纯化疗组(对照组),采用流式细胞术(FCM)和酶联免疫吸附法(ELISA)分别于化疗前后检测外周血中CD+4CDhi25CDlow127Treg细胞和血清TGF-β 1、IL-10水平,同期选取20名健康体检者为健康对照组.结果 NSCLC患者外周血中CD+4CDhi25CDlow127Treg细胞占CD+4淋巴细胞的比例为(5.77±1.50)%,与健康对照组(3.84±0.96)%相比差异有统计学意义(P=0.000);血清中IL-10和TGF-β 1表达水平[(24.09±6.74)、(197.76±43.76)ng/ml]明显高于健康对照[(19.39±5.73)、(141.13±32.17)ng/ml](P=0.006,P=0.002).对照组化疗后CD+4CDhi25CDlow127Treg细胞水平显著降低(P=0.048),细胞因子IL-10、TGF-β1的表达水平[(22.25±6.79)、(184.85±49.11)ng/ml]与化疗前[(24.37±8.10)、(197.16±44.57)ng/ml]相比差异无统计学意义(P=0.276,P=0.314).观察组化疗后CD+4CDhi25CDlow127Treg细胞和细胞因子IL-10、TGF-β1表达水平[(4.36±1.19)%,(20.16±4.73)、(165.42±39.57)ng/ml]与化疗前[(5.78±1.50)ng/ml,(23.81±5.15)、(198.35±43.68)ng/ml]相比降低,差异有统计学意义(P=0.000,P=0.006,P=0.003).结论 中晚期NSCLC患者外周血中Treg细胞表达水平增高,艾迪注射液配合化疗可以降低NSCLC患者的Treg细胞水平,改善机体免疫状态. 相似文献
10.
目的 探讨外周血CD+8 NKT细胞活化受体NKG2D及其分泌性配体sMICA检测在食管癌、贲门癌诊断及术后疗效评价中的临床意义。方法 对53例患者确诊后(29例手术患者术前14 d及术后14 d)及30名健康对照组采用流式细胞术对外周血CD+8 NKT细胞中活化受体NKG2D阳性细胞百分比测定,应用酶联免疫吸附法进行sMICA含量测定,并各自进行差异性分析,同时对两者进行依从性分析。结果 患者外周血CD+8 NKT细胞中NKG2D阳性细胞百分比为(77.632±8.972)%,明显低于对照组的(89.053±6.515)%(t=-6.113,P<0.05);TNM分期Ⅱ、Ⅲ、Ⅳ期患者依次降低(F=99.251,P<0.01);有区域淋巴结转移者均低于无区域淋巴结转移者(t=-10.384,P<0.01);鳞状细胞癌高于腺癌(t=9.899,P<0.01);术前均低于术后(t=-4.319,P<0.01)。患者血清sMICA的含量为(326.28±85.407)pg/ml,明显高于对照组的(210.00±22.560)pg/ml(t=7.292,P<0.01);Ⅱ、Ⅲ、Ⅳ期患者依次增高(F=63.355,P<0.01);有区域淋巴结转移者均高于无区域淋巴结转移者(t=7.770,P<0.01);鳞状细胞癌低于腺癌(t=-7.593,P<0.01);术前均高于术后(t=7.027,P<0.01)。血清sMICA对外周血CD+8 NKT细胞活化受体NKG2D有抑制作用(F=142.773,P<0.05),决定系数R2=0.7368。结论 外周血CD+8 NKT细胞活化受体NKG2D及其分泌性配体sMICA含量的测定有助于食管癌、贲门癌分期的临床辅助诊断,对判断其生物学行为及预后有重要临床意义,并可作为患者手术治疗效果指标。 相似文献